Igor Siniakov, MD
MOHS-Micrographic Surgery · Columbus, GANPI 1053430272
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,910 of the $2,172 with a category attached, or 87.9%. It is spread thinly across 35 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $992, more than ten times the $40 reported in 2019. That places this record below the midpoint for mohs-micrographic surgery clinicians in GA, where the typical reported total is $3,443.
Across 105 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$393
- Legend Biotech USA Inc.$273
- Regeneron Healthcare Solutions, Inc.$177
- Johnson & Johnson$130
- Amgen$121
- Sanofi$110
- plus $967 from 29 others
What the payments were for
- Speaking & faculty fees$221%
- Food & beverage$1,91088%
- Education$24011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $393 |
| Legend Biotech USA Inc. | 16 | $273 |
| Regeneron Healthcare Solutions, Inc. | 7 | $177 |
| Johnson & Johnson | 6 | $130 |
| Amgen | 5 | $121 |
| Sanofi | 4 | $110 |
| AstraZeneca(2 entities) | 5 | $110 |
| Novartis | 3 | $72 |
| LEO Pharma Inc. | 4 | $68 |
| Incyte Corporation | 3 | $60 |
| Pharmacosmos Therapeutics Inc. | 3 | $53 |
| Sobi, Inc | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Genentech USA, Inc. | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| Accord Healthcare, Inc. | 1 | $34 |
| Novo Nordisk | 2 | $33 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $27 |
| Pfizer | 1 | $26 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Array Biopharma Inc | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Geron Corporation | 1 | $22 |
| Organogenesis Inc. | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Celltrion USA Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Bayer | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Nuvation Bio Inc. | 1 | $14 |
| TG Therapeutics, Inc. | 1 | $13 |
How this compares
$2,172 in reported general payments places this provider in the 35th percentile of 40 mohs-micrographic surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 16 | $331,822 |
| HumiraAdalimumab | 11 | $131,473 |
| OtezlaApremilast | 12 | $57,282 |
| Triamcinolone Acetonide | 269 | $3,715 |
| Betamethasone Dipropionate | 40 | $2,198 |
| Doxycycline Hyclate | 63 | $1,593 |
| Ketoconazole | 85 | $1,431 |
| Clobetasol Propionate | 45 | $1,383 |
| Betamethasone Valerate | 29 | $710 |
| Metronidazole | 11 | $622 |
| Doxycycline Monohydrate | 11 | $617 |
| Minoxidil | 17 | $401 |
| Fluconazole | 23 | $357 |
| MethotrexateMethotrexate Sodium | 23 | $245 |
| Spironolactone | 21 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira | $393 | $131,47311 claims |
| AmgenOtezla | $121 | $57,28212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 40 mohs-micrographic surgery providers in Georgia.
Other mohs-micrographic surgery in Columbus
- Joshua LaneColumbus$4K
- Wallace NozileStockbridge$213K
- Brandon BurrowayDuluth$30K
- John KayalMarietta$27K
- David HarveyNewnan$17K
- David OlanskyAtlanta$13K
- David KentMacon$11K
- Diamondis PapadopoulosAtlanta$9K
- Sidney SmithSavannah$9K
- Steven KentMacon$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.